BioSpace News Archive

Molecular Templates, Inc., (Nasdaq: MTEM) a clinical-stage biopharmaceutical company focused on the discovery and development of the Company’s proprietary engineered toxin bodies (ETBs), which are differentiated, targeted, biologic therapeutics, today announced the presentations of two posters on its pipeline programs at the American Society of Hematology (ASH) 2019 Annual Meeting, taking place December 7-10, 2019 in Orlando, Florida

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer, autoimmune disease, asthma and allergic diseases, today announced initial data from its ongoing Phase 1 dose-escalation study of XmAb®13676, a CD20 x CD3 bispecific antibody, in patients with B-cell malignancies

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today presented new data from its ongoing Phase II trial ALICE, which is investigating iadademstat in combination with azacitidine in elderly patients with acute myeloid leukemia (AML).

CTI BioPharma Corp. (Nasdaq: CTIC) today announced the presentation of data from the Company’s pacritinib development program, including results from the PAC203 Phase 2 clinical trial, at the 61st American Society of Hematology (ASH) Annual Meeting being held December 7-10 in Orlando, Florida.

Seven and Eight BioPharmaceuticals Inc. announced that it has signed a clinical research collaboration agreement with Merck, through a subsidiary, to explore the combination of Seven and Eight’s BDB001, an immune modulator targeting toll-like receptors 7 and 8, and Merck’s anti-PD-1 therapy, KEYTRUDA® in treating patients with advanced solid tumors.

Evaluate Ltd., the leading provider of commercial data to the life sciences industry, is pleased to announce the appointment of Martyn Hindley as Chief Financial Officer

Aprea Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, presented preliminary results at the 2019 ASH Annual Meeting from its French Phase Ib/II clinical trial in MDS and AML.

Infiniti Research, a leading market intelligence solutions provider, has recently announced the completion of its latest success story on market intelligence solution.

Room temperature stable Vancomycin injection premix dose of 500 mg in 100 mL ready-to-use bag is now available for purchase in the US

Meeting expected to occur within thirty days of FDA’s receipt of the meeting request and meeting package